[ad_1]
A spokesman for the British pharmaceutical company told AFP that AstraZeneca was “looking to increase productivity in the EU supply chain” and would use its “global capacity to deliver 180 million tonnes to the EU in the second quarter”. dose of vaccine ‘.
“About half of the projected volume will come from the EU supply chain” and the rest from the international supply chain, added a company spokesperson.
The report was issued following problems with the delivery of a vaccine developed by AstraZeneca and the University of Oxford to the European Union in the first quarter, prompting tensions between the unit and the pharmaceutical company.
Before the vaccine was approved by the EU in late January, the company sparked outrage among European leaders by announcing that it would not meet its commitment to provide the EU with € 400 million. vaccine doses due to lack of production in European factories.
The disagreements have also sparked diplomatic tensions with Britain, which ultimately withdrew from the EU after 40 years of membership and a transition period in late 2020, with Brussels implicitly accusing AstraZeneca of favoring Britain.
Since the end of last year, the UK government has vaccinated millions of Britons with AstraZeneca.
However, the company only started supplying the vaccine to the EU in early February, when the bloc regulator finally allowed the vaccine to be used.
The AstraZeneca vaccine has suffered a number of other failures. The vaccine has been temporarily withdrawn from the South African immunization campaign due to concerns that it will be less effective against new strains of the virus. And the German vaccine commission recommended that it be given only to people aged 18 to 64.
However, more recently, experts from the World Health Organization have recommended that the vaccine be used in people over 65 and where new strains of the virus are circulating.
[ad_2]
